| Title |
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, June 2016
|
| DOI | 10.1007/s10549-016-3849-1 |
| Pubmed ID | |
| Authors |
Banu K. Arun, Yun Gong, Diane Liu, Jennifer K. Litton, Angelica M. Gutierrez-Barrera, J. Jack Lee, Lana Vornik, Nuhad K. Ibrahim, Terri Cornelison, Gabriel N. Hortobagyi, Brandy M. Heckman-Stoddard, Kimberly B. Koenig, Ricardo R. Alvarez, James L. Murray, Vicente Valero, Scott M. Lippman, Powel Brown, Nour Sneige |
| Abstract |
Selective estrogen receptor modulators (SERMs), tamoxifen, and raloxifene that reduce the risk of breast cancer are limited to only estrogen receptor-positive (ER(+)) breast cancer. In addition, patient acceptance of SERMs is low due to toxicity and intolerability. New agents with improved toxicity profile that reduce risk of ER-negative breast cancer are urgently needed. Observational studies show that statins can reduce breast cancer incidence and recurrence. The objective of this prospective short-term prevention study was to evaluate the effect of a lipophilic statin, atorvastatin, on biomarkers in breast tissue and serum of women at increased risk. Eligible participants included women with previous history of carcinoma in situ, or atypical hyperplasia, or 5 year breast cancer projected Gail risk >1.67 %, or lifetime breast cancer risk >20 % calculated by models including Claus, Tyrer-Cuzick, Boadicea, or BRCAPRO. Patients underwent baseline fine needle aspiration (FNA) of the breast, blood collection for biomarker analysis, and were randomized to either no treatment or atorvastatin at 10, 20, or 40 mg/day dose for 3 months. At 3 months, blood collection and breast FNA were repeated. Biomarkers included C-reactive protein (CRP), lipid profile, atorvastatin, and its metabolites, Ki-67, bcl-2, EGFR, and pEGFR. Baseline genotype for 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoAR) was also measured. Among 60 patients evaluated, a significant reduction in serum CRP, cholesterol and low-density lipoprotein (LDL), and increase in atorvastatin metabolites in serum and breast FNAs was demonstrated. No changes were observed in other tissue biomarkers. This study shows that atorvastatin and its metabolites are detectable in breast samples and may lower serum CRP among women without hyperlipidemia. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 80 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 17% |
| Researcher | 10 | 12% |
| Student > Bachelor | 10 | 12% |
| Student > Ph. D. Student | 8 | 10% |
| Other | 4 | 5% |
| Other | 14 | 17% |
| Unknown | 21 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 10% |
| Biochemistry, Genetics and Molecular Biology | 6 | 7% |
| Psychology | 4 | 5% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 29 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 July 2016.
All research outputs
#17,808,979
of 22,877,793 outputs
Outputs from Breast Cancer Research and Treatment
#3,577
of 4,659 outputs
Outputs of similar age
#245,687
of 345,199 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#61
of 106 outputs
Altmetric has tracked 22,877,793 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,659 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,199 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 106 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.